Proton pump inhibitors sales will grow through 2036, led by omeprazole at 30% of the drug type segment in 2026. The market was valued at USD 3.20 billion in 2025 and is expected to be worth USD 5.59 billion by 2036, creating an incremental opportunity of USD 2.22 billion.